Introduction
Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus has been implicated in the development of all epidemiological forms of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). KS is a multifocal tumor, which affects the skin, visceral organs and lymph nodes. The KS lesions are characterized by proliferating spindle cells, prominent angiogenesis and leukocyte infiltration. The DNA of HHV-8 is found in the spindle cells and endothelial cells of the KS lesion suggesting that their presence has a critical role in the induction and maintenance of the tumor (Chang et al., 1994) . This is further supported by the fact that the HHV-8 genome contains several genes capable of causing oncogenic transformation and immunological disturbances. However, viral oncogenesis seems to depend on other cofactors such as cytokine dysregulation and the functional state of the immune system (Flore et al., 1998; Gallo, 1998; Monini et al., 1999; Samaniego et al., 2002) .
HHV-8 encodes a chemokine receptor homolog (vGPCR), which may play an important role in virusmediated tumorigenesis. vGPCR is a constitutively active receptor, which binds several CC and CXC chemokines and its activity is modulated by a number of CXC chemokines, for example, CXCL10 (Arvanitakis et al., 1997; Gershengorn et al., 1998) . Ectopic expression of vGPCR in NIH3T3 cells causes oncogenic transformation and leads to the upregulation of vascular endothelial growth factor (VEGF), a potent mitogen for spindle cells and endothelia (Bais et al., 1998) . It has been suggested that vGPCR might participate in KS pathogenesis in an autocrine/paracrine fashion by inducing the secretion of VEGF and by maintaining an angiogenic phenotype through signaling via a VEGFR2/ VEGF loop (Bais et al., 2003) . Further, it has recently been reported that the continued vGPCR expression is essential for progression of KS-like phenotype (Jensen et al., 2005) .
The growing evidence for vGPCR's possible participation in the HHV-8-associated oncogenesis emphasizes the need for establishing animal models to address the mechanisms of its involvement in vivo. The potential of vGPCR to induce tumors was initially demonstrated in nude mice, where NIH3T3 cells ectopically expressing vGPCR gave rise to highly vascularized tumors histopathologically similar to human KS (Bais et al., 1998) . More recently, transgenic mice expressing vGPCR in different cellular backgrounds have provided additional support for vGPCR's critical role in the genesis of KS (Yang et al., 2000; Holst et al., 2001; Guo et al., 2003; Montaner et al., 2003) .
The target cells infected initially during the development of HHV-8-associated diseases have not been clearly identified. HHV-8 DNA and transcripts have been detected in KS spindle cells, epithelial cells, keratinocytes, fibroblasts, B cells and macrophages, suggesting that the virus infects a wide variety of cells in vivo (Kaaya et al., 1995; Cerimele et al., 2001; Akula et al., 2003) .
In this report, we show that tumors induced in BALB/ c nude mice by injection of vGPCR-expressing NIH3T3 or BALB/c3T3 fibroblasts can be transplanted with high efficiency in immunocompetent BALB/c mice. Furthermore, cells isolated from transplanted tumors on reinfusion are highly tumorigenic in immunocompetent mice with the resultant mesenchymal tumors showing a striking morphological resemblance to KS.
Results

Functional and expression analysis of vGPCR
To test whether the myc-epitope at the C-terminus of vGPCR interfered with its signaling activity, mitogenactivated protein kinases (MAPK) assays with the tagged wild-type vGPCR and its functionally defective mutant p-AvGPCR-myc were performed after transfection of the respective plasmids in CHO-K1 cells (Figure 1a) . Without ligand stimulation, transfection with the wild-type vGPCR-myc led to an approximately 10-fold increase of MAPK activity (Figure 1a ), demonstrating its constitutive signaling in agreement with previous reports (Arvanitakis et al., 1997) . The activity of the mutant remained at baseline levels comparable to that of the empty vector pcDNA3.1, and collectively the results show that vGPCR constructs are functional.
Flow cytometric analysis with vGPCR-specific monoclonal antibody 7D1 (generated against the extracellular N-terminus) distinctly detected the surface expression of vGPCR in HEK293 cells (Figure 1b (Figure 1e ), whereas the myc-epitope was only detected after the cells had been permeabilized (Figure 1f ). NIH3T3 cells selected for high expression of vGPCR were analysed for their ability to form tumors after subcutaneous (s.c.) injection into male athymic BALB/c mice. Eight vGPCR-myc expressing cell lines were selected and all gave rise to progressively growing tumors at the site of inoculation. Tumors were detected within 7-14 days after injection and the animals were killed usually between 20 and 40 days, when the tumor diameter was about 2 cm ( Figure 2a ). Within this observation period, no tumors were seen in animals that received vector or non-transduced NIH3T3 cells. 
Tumorigenicity of transplanted tumor fragments in immunocompetent mice
Immunocompetent mice did not develop tumors after s.c. injection of parental vGPCR or Ras expressing NIH3T3 (H-2 q ) cell suspensions. In an attempt to develop a vGPCR-based tumor model in immunocompetent mice, tumor fragments were excised under aseptic conditions from nude mice and transplanted s.c. to BALB/c mice (H-2K d ). As judged by physical inspection and histology, the tumor fragments grafted efficiently in all BALB/c mice (n ¼ 12, Figure 2b ). Although macroscopic metastases were not apparent, but cells obtained from lungs, lymph nodes and tail grew in medium containing puromycin indicating the presence of the integrated proviral transgenes. Expression of vGPCR in the cells harvested from the tumor and peripheral organs was confirmed (Figure 3) . Notably, cells isolated from the tumor showed higher vGPCR expression than the parental cells injected in nude mice (Figure 3d and e), suggesting that further selection or accumulation of additional molecular alterations that might have occurred in vivo. Ras-tumor fragments from nude mice on transplantation also survived in all immunocompetent Tumorigenicity of viral chemokine receptor vGPCR N Thirunarayanan et al mice, whereas vector-derived spontaneous tumor grafts did not ( Figure 2b ).
Tumorigenicity of tumor-derived vGPCR cell lines in immunocompetent mice
Cell lines (T1-T4) were established from individual vGPCR tumors from four immunocompetent mice and their tumorigenic potential was evaluated by s.c. injections (5 Â 10 5 cells/animal) into the flanks of immunocompetent mice. Surprisingly, two of the animals injected with T2 and one from each of the mice injected with T1, T3 and T4 developed tumors 6 days after injection ( Table 1) . The experiments were repeated using tumor cells, T5 and T6 (1 Â 10 6 cells/animal, n ¼ 11 and n ¼ 12, respectively), derived from other two independently transplanted animals and the tumor incidences within 14 days were 81% (nine of 11) and 66% (eight of 12), respectively (Table 1) . However, some of the mice (three of nine in T5 and one of eight in T6 group) rejected the tumors within 21 days. To assess whether repeated passaging of tumor cells in immunocompetent mice would increase tumorigenicity, additional cells lines, T7 and T8, were isolated from tumors induced by T5. Eighty percent of the mice injected with T7 or T8 (1 Â 10 6 cells/animal) developed tumors within the first week. However, the tumors showed signs of regression in the second week but surprisingly reappeared as aggressive tumors at the same site after a dormancy period of approximately 2 months (Table 1) . Similar to the situation in animals transplanted with tumor fragments, circulating tumor cells could be isolated from the lungs and lymph nodes (T9 and T10, respectively). Both cells lines retained the ability to form tumors in immunocompetent mice with T9 inducing tumors in all of the animals injected (Table 1) . To further assess the tumorigenic potential of T9, 1 Â 10 6 cells were injected directly into the tail vein. Of the eight animals injected with T9, three developed tumors in the lung and tail (not shown). One animal showed distant tumor manifestations in the abdominal wall, the stomach and the large intestine and also had abnormally large Peyer's patches (not shown) and mesenteric lymph nodes, which contained vGPCRexpressing tumor cells (Figure 3) . None of the animal injected intravenously with NIH3T3-expressing vGPCR (clone 216) or vector control developed tumors.
However, tumors of NIH3T3-based tumor cells regressed unexpectedly in some experiments and also considering the vital role of MHC class I antigens in immune surveillance, we investigated the possible development of tumor model in immunocompetent BALB/c host based on syngeneic BALB/c3T3 (H-2K d ) cells instead of allogenic NIH3T3. vGPCR-expressing BALB/c3T3 cells were injected s.c. in nu/nu mice, where only two of five mice developed tumors after the latent period of 2 months. On subsequent transplantation, these nude mouse-derived grafts also established tumors in immunocompetent mice, and further obtained cells (BT1 and BT2; Table 1 ) formed tumors more progressively ( Figure 2c ) in all mice without signs of regression demonstrating their enhanced tumorigenicity and immunoresistance in syngeneic host compared to NIH3T3 counterparts. Surprisingly, but remarkably cell lines (TRas4 and TRas5) isolated from transplanted immunocompetent mice Ras tumors also induced tumors with 100% incidence (Figure 2c ).
Specificity of vGPCR tumorigenicity
It is rarely expected that 3T3 cells may spontaneously get transformed to some degree and contribute to tumorigenicity. In order to confirm that tumorigenesis in this model is specifically driven by vGPCR, the tumors were induced with tumor-derived cell line, BT1, expressing short interfering hairpin RNAs (shRNA) directed at vGPCR (Figure 4a-c) . After 40 days of s.c. implantation, 75% of control-shRNA-expressing cells induced tumors of maximum size, whereas vGPCRshRNA-expressing cells could interestingly form smaller sized (threefold reduction) tumors (Figure 4d ). The significant reduction in tumor growth kinetics by shRNA strongly implies that vGPCR specifically contributes to the tumorigenesis. In an additional approach of demonstrating vGPCR-specific tumorigenesis, BT3 tumor cells expressing varying levels of vGPCR (Figure 4e-g) were injected s.c. to immunocompetent mice. All mice treated with vGPCR-high cells formed tumors reaching maximum permissible size at days 21-28 whereas both vGPCR-intermediate and vGPCR-lowinjected mice started forming tumors at third or fourth week in 75% of mice (Figure 4h ). These tumors including vGPCR-low have further shown the expression of vGPCR in varying abundance on either 
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Discussion
The present study demonstrates for the first time the tumorigenic potential of tumor-derived NIH3T3 and BALB/c3T3-based cells expressing vGPCR in immunocompetent BALB/c mice. To this end, we generated vGPCR-expressing 3T3 fibroblasts using retroviral gene transduction. The expression of the transduced vGPCR in 3T3 cells was verified using vGPCR-specific monoclonal antibody 7D1, which was designed to detect an epitope within the extracellular N-terminus. In addition the functional integrity of transduced vGPCR could be demonstrated in vitro by MAPK activation. Subcutaneous injections of these cells into nude mice resulted in the formation of highly vascularized tumors, confirming the oncogenic activity of epitope-tagged vGPCR (Bais et al., 1998) . Interestingly, implantation of tumor fragments from nude mice into their immunocompetent counterparts led to the rapid local development of tumors as has been described for highly antigenic sarcomas (Ochsenbein et al., 1999) . However, vGPCR-induced tumors were histologically similar to those described in immunodeficient mice injected with vGPCR-transfected cells (Bais et al., 1998) and vGPCRtransgenic mice (Yang et al., 2000; Guo et al., 2003) .
Growth of subcutaneously implanted tumor fragments in immunocompetent hosts has been attributed to failure of the tumor cells to reach organized lymphoid organs resulting in the insufficient presentation of the tumor associated antigens (Ochsenbein et al., 2001) . We have recently shown that, in a model of acute allogeneic tumor rejection, CCR7À/À mice completely failed to reject subcutaneously injected MHC class I mismatched tumor cells and cytotoxic activity of allospecific T cells was severely compromised (Ho¨pken et al., 2004) . In this study, however, NIH3T3 cell (H-2 q )-derived tumors were expected to be rejected by the BALB/c (H-2K d ) recipient mice. Despite the incompatibility in MHC molecules, the tumor fragments did not only grow rapidly in their immunocompetent hosts, but individual tumor cells were apparently able to detach from the primary tumor allograft and intravascularly spread to distant organs, such as the intestines, lungs and lymph nodes. Moreover, analysis of the cells isolated from the tumor showed increased levels of vGPCR expression compared to parental cells, suggesting that selection had taken place in vivo favoring cells with high vGPCR expression. The ability of vGPCR-expressing NIH3T3 cells to survive immune surveillance could be a result of as yet unknown immunomodulatory effects of vGPCR, and also other molecular changes occurred during tumor progression.
In an additional approach, suspensions of vGPCRtransduced cells isolated from solid tumors and expanded in culture were subcutaneously injected in immunocompetent mice. Similar to the tumor fragments, the cell suspensions surprisingly gave rise to tumors morphologically resembling KS. In contrast, parental NIH3T3-expressing vGPCR (clone 216) or those isolated from tumors induced in nude mice did not induce tumors in immunocompetent mice. Noteworthy, like vGPCR-transduced fibroblasts, NIH3T3 cells transformed with the strong prototype oncogene Ras acquired the ability to induce tumors in immunocompetent mice only on passage through nu/nu mice. These results suggest a more general mechanism how these tumor-derived cell lines might escape from tumor surveillance.
Studies in human KS and animal models have indicated that the expression of vGPCR is limited to a minority of cells in the tumor leading to the notion that vGPCR might support tumor growth via paracrine effects on other cells (Kirshner et al., 1999; Cesarman et al., 2000; Yang et al., 2000; Pati et al., 2001; Chiou et al., 2002) . Using the novel vGPCR-specific mAb 7D1, we were able to confirm expression of vGPCR in BCBL1 cells as well as on paraffin-embedded sections of KS, PEL and MCD (ML, unpublished). Immunohistological analysis of the tumors in our models using mAb 7D1 reveals, however, that vGPCR expression in the tumor is heterogeneous, that is, comprising sections with very low and high vGPCR expression, probably corresponding to areas with predominant paracrine and autocrine activation, respectively. Accordingly, low vGPCR-expressing sections revealed the protuberance of high degree of neovasculature as shown by CD31 and VEGFR2-positive cells. High-level expression of both endothelial markers CD31 and VEGFR2 has also been found in human KS. VEGFR2 is exclusively expressed on endothelial cells and activation by its ligand VEGF is critical for tumor angiogenesis (Brekken and Thorpe, 2001 ). Enhanced expression of VEGF has been demonstrated in NIH3T3 cells expressing vGPCR, within KS lesions and in vGPCR-induced tumors in other models (Bais et al., 1998; Skobe et al., 1999; Yang et al., 2000; Guo et al., 2003; Montaner et al., 2003) . The high concentration of VEGF in the tumor environment could cause migration of endothelial cells towards the growing tumor to establish the vascular network that facilitates tumor growth and metastases. Intratumoral lymphocytes both of T-and B-cell lineage were present in moderate abundance. B cells have been shown to be directly involved in the control of tumor growth (Qin and Blankenstein, 1995; Quan et al., 1999) . The infiltrating B cells in our model could be the result of an ongoing immune response against the tumor cells that may also account for the spontaneous regression of some tumors. However, it cannot be ruled out that the B cells are recruited by chemokines produced in the tumor.
Clearly tumor growth observed in immunocompetent mice does not result from a chance anomaly during passaging in a single immunocompetent host, as cells isolated from several tumors grown in different animals were tumorigenic, and also control could not form tumors in immunocompetent host. Furthermore, introduction of shRNA directed at vGPCR resulted in significantly delayed tumor response supporting the specificity of vGPCR tumorigenesis. Higher expression of vGPCR alone cannot account for the increased tumorigenicity, as cells isolated from tumors (not fragments) induced in the immunodeficient BALB/c mice were not tumorigenic in their immunocompetent counterparts yet exhibited similar levels of vGPCR expression (not shown). It is conceivable that passaging the tumors in immunocompetent hosts may allow for subtle changes in genomic integrity in vGPCR-transduced 3T3 fibroblasts, which lead to the tumor cells ability to survive in immunocompetent hosts. This might also account for the enhanced tumorigenic phenotype of the tumor cells established from vGPCR-transgenic mice (Guo et al., 2003) . Currently, there is no consensus on the degree of genomic lesions in human KS or data globally assessing the genomic integrity of the KS-like lesions in murine transgenic models.
In summary, we have demonstrated that tumors induced in nude mice by vGPCR-expressing NIH3T3 and BALB/c3T3 cells can be transplanted with high efficiency to immunocompetent BALB/c mice. Contrary to our expectations, tumor-derived vGPCR-expressing cells evolve to an enhanced tumorigenic phenotype after a single passage in immunocompetent mice. Although we have not yet identified the underlying cellular and molecular mechanisms, the progressively growing tumors might evade their own destruction by becoming poorly immunogenic or provide a microenvironment efficiently inducing T-cell tolerance. Our model represents a novel approach for studying the role of vGPCR in HHV-8-mediated oncogenesis, which may help in testing new therapies for HHV-8 associated diseases. This model will also be valuable in identifying critical molecular epigenetic changes, which might have evolved during the process of tumor progression.
Materials and methods
Plasmid construction
The full-length vGPCR was amplified from the genomic DNA of BCBL1 cells using the following primers: forward, 5 0 -CGCAAGCTTAGCATGGCGGCCGAGGATTTCC-3 0 ; reverse, 5 0 -GCTCTAGAGGAGATCTTCCTCAGATATCAGCT TCTGCTCGGGCCCAGATCCTCCAGGCGTGGTGGCGCC GGACATG-3 0 . The resulting product (p-vGPCR-myc), harboring a myc-tag (letters in italics) downstream of vGPCR, was cloned into pcDNA3.1 þ (Invitrogen, Carlsbad, CA, USA). A mutant p-AvGPCR-myc, in which all the amino acids in the third intracellular loop are substituted with alanine (bold) to prevent the coupling of G protein to the receptor, was generated by cloning the two fragments amplified from vGPCR-myc using the following primers: first fragment forward, 5 0 -CGGGGCTAGCATGGCGGCCGAGGATTT CC-3 0 ; reverse, 5 0 -GCACCGGTGAGAGCATAAAACAGA ATAAGG-3 0 . The second fragment forward, 5 0 -CGACCGG TGCAGCCGCGGCTGCAGCCGCGGCTGCAGCCGCGGC TGCAGCCGCCGGCGTGATTGTGGCTGTGGTGC-3 0 and the reverse primer as in p-vGPCR-myc. vGPCR-myc was inserted into the retroviral expression vector pBabe-puro (Morgenstern and Land, 1990) to produce pBabe-vGPCRmyc. pBabe-green fluorescent protein (GFP) was a gift from Dr Zenke (Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany).
Cell lines
All cell lines were obtained from the American Type Cell Culture Collection (Manassas, VA, USA) and maintained in Dulbecco's minimum essential medium (DMEM) supplemented with 10% (vol/vol) heat inactivated fetal calf serum (FCS). BALB/c3T3 and tumor-derived cell lines were grown with 10% newborn calf serum (Biochrome, Berlin, Germany). The packaging cell line Phoenix-Eco (kindly authorized by Dr Nolan, Stanford University, CA, USA) was grown in DMEM with high glucose (4500 mg/l). The cells containing retroviruses were selected and maintained in media containing 2 mg/ml of puromycin (Sigma, St Louis, MO, USA). Ha-RasG12 Vtransformed NIH3T3 (NIHpEJcl3) were provided by Blankenstein, MDC (Berlin, Germany).
FACS analysis, Western blot and antibodies FACS and Western blot analysis were performed as described (Emrich et al., 1993) . The following antibodies and conjugates were used: donkey-anti-rat-PE (Jackson ImmunoResearch Laboratories, Westgrove, PA, USA); mouse-IgG1-FITC and mouse-IgG1-PE (Immunotech, Marseille, France); rat-IgG2a, anti-CD3-PE, anti-VEGFR-2-PE and anti-MHCII-PE (Pharmingen, San Diego, CA, USA); anti-Ly5 (B220; clone RA3-6B2)-FITC (Caltag, Burlingame, CA, USA); rat anti-vGPCR (clone 7D1; generated as described below) and mouse anti-myc (clone 9E10; Emrich et al., 1993) .
Production of vGPCR-specific mAb 7D1
A PCR fragment containing the first N-terminal 77 amino acids of vGPCR was cloned in pGEX-2T (Amersham Biosciences, Piscataway, NJ, USA) using the following primers: forward, 5 0 -CGGGATCCATGGCGGCCGAGGATTTC-3 0 ; reverse, 5 0 -GCGAATTCTCAAATGTAGGTGACCAATCC-3 0 . The GST-vGPCR fusion protein was produced in Escherechia coli and purified as recommended. The production of the mAbs was carried out as described earlier (Fo¨rster et al., 1998) . In brief, Luo rats were immunized with 100 mg of GSTvGPCR in CFA and boosted once with the same amount of antigen. Hybridomas were initially screened for specific antibody production by differential enzyme-linked immunosorbent assay using GST-vGPCR and a panel of irrelevant GST fusion proteins as control. Further screening was performed by FACS analysis of HEK293 cells transfected with p-vGPCR or empty vector. Two mAbs designated 5H2 and 7D1 were found to react specifically with p-vGPCRtransfected cells.
MAP kinase assay
The PathDetect ELK-1 Trans-Reporting System (Stratagene, La Jolla, CA, USA) was used in combination with the dual luciferase reporter assay system (Promega, Madison, WI, USA) to assess the MAP kinase activation by vGPCR in CHO-K1, CV-1, HEK293 and HeLa cells as previously described (Mu¨ller and Lipp, 2001 ).
Retroviral production and transduction
Phoenix-Eco packaging cells were transfected with 15 mg DNA (pBabe-vGPCR-myc or pBabe-GFP). Four days after transfection, the cells were splitted (1:20) to select on puromycincontaining medium. Supernatants were collected from clones with high transgene expression and titrated on NIH3T3 cells. NIH3T3 or BALB/c3T3 cells with 40-50% confluence were infected using viral supernatants diluted in DMEM containing 5% FCS and 8 mg/ml polybrene (Sigma), and after 4 h 5 ml fresh medium (DMEM, 5% FCS) was added. After 72 h the cells were then splitted (1:20) and subjected to puromycin selection for around 7 days. The high vGPCR-expressing clones were chosen to use in further experiments.
Tumor induction in mice Athymic BALB/c (nu/nu) and BALB/c mice were obtained from the animal facility of Max-Delbru¨ck Center and housed under specific pathogen-free conditions. All experiments were performed in compliance with institutional and legal guidelines. Tumors were induced by s.c. injection with retrovirustransduced vGPCR or Ras-expressing 3T3 cell lines (half to one million cells in 100 ml phosphate-buffered saline) in the flank of nude mice at the age of 7-14 weeks. Mice were observed at weekly intervals for tumor formation. Tumors obtained from nude mice were cut into small pieces (approximately 8 mm 3 ) and transplanted s.c. to immunocompetent mice which were anaesthetized. All tumors and grossly unremarkable individual organs (liver, kidneys, lungs, heart, gonads and gastrointestinal tract) were formalin fixed and paraffin embedded in their entireties.
Generation of cell lines from tumors and organs
The tumors and organs were minced and placed in 10 cm culture plates containing DMEM. Media was changed every third day for 2-3 weeks with fresh medium containing puromycin. After reaching confluence, puromycin-resistant cells were analysed for vGPCR expression. Similarly, the cell lines, TRas4 and TRas5, were generated from Ras tumors using Roswell Park Memorial Institute media without puromycin.
Generation of shRNA-expressing lentiviruses and vGPCR silencing
The vGPCR expression was silenced down by lentiviral transduction of pLL3.7-expressing vGPCR-specific shRNA template, which comprised 21-nt inverse repeats of target separated by 9-nt loop sequence. The mismatch controlshRNA template had two substitutions in the target. The cloning of targets in pLL3.7 and lentivirus production were performed as described (Rubinson et al., 2003 and http:// web.mit.edu/ccr/labs/jacks/protocols/rnairesources.htm). Confluently grown vGPCR-expressing cells were transduced twice on consecutive days with the appropriate amounts of supernatants containing 8 mg/ml polybrene. After 3 days, the transduction efficiency and vGPCR silencing were ascertained based on GFP and vGPCR expression respectively, by FACS, and highly GFP-positive-transduced population obtained by FACS sorting (FACSvantage; BD Biosciences, Mountain View, CA, USA) were then used for further experiments.
Immunofluorescence
Cryosections were prepared and stained as described before (Fo¨rster et al., 1998) using the following antibodies: antivGPCR (dilution, 1:200), anti-rat-cy2, anti-rat-Cy3, anti-goatcy3 or anti-rat-Cy5 (Jackson ImmunoResearch Laboratories), anti-VEGFR2-PE, anti-MHCII-PE (Pharmingen) and goat anti-CD3 (Santa Cruz, CA, USA). After mounting in Moviol (Calbiochem, San Diego, CA, USA) the slides were analysed by confocal microscopy (Zeiss, Meta 500; Carl Zeiss, Oberkochen, Germany).
Immunohistochemistry
Informative sections of formalin-fixed, paraffin-embedded tumor blocks from immunocompetent mice were immunostained essentially as described (Ko¨lble et al., 1999) .
